View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, April 26 (HealthDay News) -- A selective negative allosteric modulator of the metabotropic glutamate receptor subtype 5 (mGluR5), GRN-529, improves some behavioral features of autism in mouse models of the disorder, according to an experimental study published in the April 25 issue of Science Translational Medicine.
Noting that inhibitors of the mGluR5 are in clinical trials for fragile X syndrome, and about 30 percent of these patients have autism, Jill L. Silverman, Ph.D., from the National Institute of Mental Health in Bethesda, Md., and colleagues examined the efficacy of the mGluR5 inhibitor GRN-529 in an established mouse model with behavioral phenotypes relevant to the three diagnostic behavioral symptoms of autism (BTBR).
In BTBR mice, the researchers found that, at non-sedating doses, GRN-529 reduced repetitive behaviors and partially reversed lack of sociability on some measures of social approach and reciprocal social interactions. However, GRN-529 did not improve impaired communication in the mice. In a second inbred strain of mice, the same non-sedating doses reduced the characteristic, spontaneous stereotyped jumping.
"These findings raise the possibility that a single targeted pharmacological intervention may alleviate multiple diagnostic behavioral symptoms of autism," Silverman and colleagues conclude.
The study was partly funded by Pfizer; several authors are employees of Pfizer.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top